Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
FDA (for muromonab-CD3)
|
| gptkbp:discontinued |
gptkb:muromonab-CD3_(in_US)
|
| gptkbp:example |
gptkb:muromonab-CD3
gptkb:otelixizumab gptkb:teplizumab |
| https://www.w3.org/2000/01/rdf-schema#label |
anti-CD3 antibody
|
| gptkbp:mechanismOfAction |
T cell depletion
T cell inactivation |
| gptkbp:notableCase |
type 1 diabetes prevention
|
| gptkbp:sideEffect |
fever
headache chills cytokine release syndrome increased risk of infection |
| gptkbp:structure |
gptkb:IgG
|
| gptkbp:target |
gptkb:CD3
|
| gptkbp:usedFor |
immunosuppression
treatment of autoimmune diseases treatment of transplant rejection |
| gptkbp:bfsParent |
gptkb:Cytokine-induced_killer_cell
|
| gptkbp:bfsLayer |
6
|